Home
News
Create
Screeners
Insights
Vivimed Labs
7.
75
+0.36
(+4.87%)
Market Cap
₹64.26 Cr
PE Ratio
-1.76
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+4.87%
1M
+17.25%
6M
-70.86%
1Y
-70.86%
5Y
+24.00%
View Company Insights
Latest news about Vivimed Labs
NCLT Admits Vivimed Labs to Corporate Insolvency Resolution Process Over ₹2.79 Crore Debt
21 hrs ago
Yesterday
NCLT Bengaluru has admitted Vivimed Labs Limited to Corporate Insolvency Resolution Process on April 15, 2026, following a petition by German creditor Blue Cube Germany Assets GmbH & Co. KG over unpaid operational debt of ₹2,78,60,844. The debt originated from supply of perchloroethylene between 2012-2014, with the company failing to honor repayment undertakings made in 2021 despite obtaining a civil court decree in 2019. T Narayana Swamy has been appointed as Interim Resolution Professional, and a comprehensive moratorium has been imposed on all legal proceedings against the pharmaceutical company.
Vivimed Labs Submits Q4FY26 SEBI Compliance Certificate to Stock Exchanges
9 days ago
Vivimed Labs Reports Widened Q3 FY26 Loss at ₹165.66 Million on Lower Revenue
Mar 13, 2026
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO